Collision and Composite Tumors; Radiologic and Pathologic Correlation

Total Page:16

File Type:pdf, Size:1020Kb

Collision and Composite Tumors; Radiologic and Pathologic Correlation UC Irvine UC Irvine Previously Published Works Title Collision and composite tumors; radiologic and pathologic correlation. Permalink https://escholarship.org/uc/item/7zc5h908 Journal Abdominal radiology (New York), 42(12) ISSN 2366-004X Authors Sung, Calvin T Shetty, Anup Menias, Christine O et al. Publication Date 2017-12-01 DOI 10.1007/s00261-017-1200-x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ª Springer Science+Business Media New York 2017 Abdom Radiol (2017) Abdominal DOI: 10.1007/s00261-017-1200-x Radiology Collision and composite tumors; radiologic and pathologic correlation Calvin T. Sung,1,2 Anup Shetty,3 Christine O. Menias,4 Roozbeh Houshyar,1 Shreya Chatterjee,1 Thomas K. Lee,1 Paul Tung,1 Mohammed Helmy,1 Chandana Lall1 1Department of Radiological Sciences, Irvine School of Medicine, University of California, 101 The City Drive South, Suite #1105, Orange, CA 92868, USA 2School of Medicine, University of California Riverside, 900 University Ave., Riverside, CA 92521, USA 3Department of Radiology, Washington University School of Medicine in St. Louis, 510 South Kingshighway Boulevard, St. Louis, MO 63110, USA 4Department of Radiology, Mayo Clinic, Phoenix, AZ 85054, USA Abstract and immunohistochemically distinct neoplasms coexist- ing within the proximity of the same organ; however, The terms composite and collision tumors have been they have actual cellular intermingling and a common used interchangeably throughout radiological literature. driver mutation that results in divergent histology from a Both composite and collision tumors involve two mor- common source [4, 5]. Although there is no consensus for phologically and immunohistochemically distinct neo- defining synchronous tumors, they generally refer to two plasms coexisting within a single organ. However, behaviorally and histologically distinct tumors that are collision tumors lack the histological cellular intermin- physically separated but occur simultaneously or fol- gling seen in composite tumors. Composite tumors often lowing each other in sequence by less than 2 months [6]. arise from a common driver mutation that induces a The presence of two different cell types can lead to per- divergent histology from a common neoplastic source plexing imaging findings, which at times, makes the while collision tumors may arise from coincidental neo- diagnosis of a collision or composite tumor challenging plastic change. The purpose of this review is to provide and may necessitate a biopsy for confirmation. an overview of abdominal composite and collision tu- Currently there are three hypothesis regarding the mors by discussing hallmark radiographic and patho- pathogenesis of composite and collision tumors. The logical presentations of rare hepatic, renal, and adrenal simplest, although not necessarily the most likely, case studies. A better understanding of the presentation explanation is the coincidental occurrence of two pri- of each lesion is imperative for proper recognition, mary neoplasms within a common location. A second diagnosis, and management of these unique tumor pre- hypothesis suggests that a common carcinogenic stimu- sentations. lus may have altered the cellular microenvironment within the proximity of which two distinct neoplasms Key words: Biphenotypic—Composite hepatocellular arise from. Similarly, the last hypothesis suggests that the and cholangiocarcinoma—Live collision—Composite first tumor may have altered the microenvironment renal cell carcinoma—Collision within the organ and increased the likelihood of devel- cholangiocarcinoma—Renal collision—Adrenal collision oping another primary tumor or facilitated metastatic seeding within the vicinity [7]. Composite and collision tumors are extremely rare, considering that only 63 cases By definition, the term collision tumor refers to inde- of collision tumors were reported in 2015 [3]. While pendently coexisting neoplasms with different behav- imaging alone may not be sufficient to diagnose the tu- ioral, genetic, and histological features that are sharply mors involved, it is imperative to clinically recognize the demarcated and lack significant tissue admixture [1–3]. duality of these lesions since the biopsy of only a single Composite tumors also comprised two morphologically component may result in an incomplete diagnosis, sub- optimal treatment, and adverse consequences. In the Correspondence to: Chandana Lall; email: [email protected] C. T. Sung et al.: Collision and composite tumors; radiologic and pathologic correlation following section, we will correlate the imaging findings hepatitis B or C, aflatoxin exposure, steatohepatitis, and histopathology of composite and collision tumors of hereditary hemochromatosis, and alpha-1-antitrypsin hepatobiliary, renal, and adrenal origins. deficiency with or without cirrhosis, which is the greatest single risk factor for developing HCC [25]. CC is an Hepatobiliary composite tumors adenocarcinoma that arises from the biliary epithelium due to parasitic infections, biliary duct cysts, and pri- The co-existence of hepatocellular carcinomas (HCCs) mary sclerosing cholangitis [26]. CCs are divided into and cholangiocarcinoma (CCs) is the most commonly intrahepatic (20%) and extrahepatic (80%) tumors based described form of composite (combined or mixed) tumor not only on anatomic location but also differences in according to literature, even though this type of lesion their risk factors, clinical presentations, and therapies constitutes less than 1% of all HCCs [2, 8]. Hepatocel- [27]. lular cholangiocarcinomas (HCC–CCs) are primary liver Detailed histopathologic evaluation with specific composite carcinomas with biphenotypic differentiation immunohistochemistry (IHC) markers is also critical in that stem from either common progenitor cell lineages or confirming the diagnosis of HCC–CC. Immunohisto- the dedifferentiation of mature liver cells [9]. Studies chemistry markers for HCC include CD 10, alpha-feto- indicate that HCC–CCs have a worse prognosis than protein (aFP), cytoplasmic hepatocyte paraffin 1, and either HCC or CC alone [10–16]. Treatment modalities polyclonal CEA, while biliary markers for CC include include local radiofrequency ablative therapy, the carbohydrate antigens keratin 7 and 19 [28, 29]. Al- chemotherapy, transarterial chemoembolization, liver though these tumor markers are not extremely specific or transplantation, and radical resection, which is preferred sensitive for HCC–CC, it is important to consider HCC– over nonoperative management in terms of survival CC if both markers are overlapping or if the antigens outcome (16.5 months) [13, 15, 17, 18]. Approximately corresponding to one tumor are elevated in discordance. 20% of all liver transplants in the United States are Polyclonal CEA when present with cytoplasmic hepato- performed for HCC, and current guidelines state that cyte paraffin 1 is sufficient for the diagnosis of HCC. CC pathologic proof is not required if MRI and CT imaging in cirrhotic livers is difficult to diagnose and may be with contrast is concordant [18, 19]. Before conducting mistaken for HCC, which further reinforces the impor- invasive treatment prior to pathology, the findings that tance of utilizing serum tumor markers and atypical HCC–CC has a 78% 5-year recurrence rate compared to vascular enhancement patterns along with core needle 17% in HCC patients should be considered in regards to biopsies to reach a proper diagnosis (Figs. 1, 2, 3). the patient’s prognosis despite the fact that HCC–CCs constitute less than 1% of all HCCs [9, 20]. Composite hepatocellular carcinoma Primary malignant liver tumors resemble and arise and cholangiocarcinoma from major constituent liver cells [21]. For example, hepatocytes give rise to HCC, biliary epithelial cells to Classic discriminating features such as biliary duct dila- CC and biliary cystadenocarcinoma, and endothelial tion and characteristic enhancement patterns may not cells to angiosarcoma and epithelioid hemangioen- always be present [9]. The degree of attenuation, signal dothelioma [21]. When determining etiology, it should be intensity, and specific enhancement patterns relate to the noted that metastases outnumber primary liver malig- proportional dominance and distribution of the HCC nant tumors 30–1 [21]. Composite HCC–CC is and CC component within the composite tumor [30]. acknowledged as a distinct subtype of CC [22, 23]. World Dynamic contrast-enhanced MRI and CT are the Health Organization (WHO) guidelines define HCC–CC imaging modalities of choice [31]. HCC characteristically as a tumor with unequivocal, intermixed elements of display arterial hyperenhancement with washout during HCC and CC [19]. HCC–CC is subdivided into type A the portal venous or delayed phase and a hallmark (separate foci of HCC and CC within the same liver enhancing pseudocapsule on delayed phase images [31]. lobe), type B (adjacent HCC and CC comingling with HCC is also strongly associated with vascular invasion of continued growth), and type C (components of HCC and the portal or hepatic venous system CCs have varied CC within the same mass) according to the Allen and enhancement patterns but generally display a continuous Lisa’s classification scheme [9, 24]. Similarly, Goodman peripheral rim enhancement during early phase with et al. categorized HCC–CC with type I tumors (HCC hyperenhancement in the central portion of the tumor and CC within the same liver),
Recommended publications
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Primary Oncocytic Carcinoma of the Salivary Glands: a Clinicopathologic and Immunohistochemical Study of 12 Cases
    Oral Oncology 46 (2010) 773–778 Contents lists available at ScienceDirect Oral Oncology journal homepage: www.elsevier.com/locate/oraloncology Primary oncocytic carcinoma of the salivary glands: A clinicopathologic and immunohistochemical study of 12 cases Chuan-Xiang Zhou a,1, Dian-Yin Shi b,1, Da-quan Ma b, Jian-guo Zhang b, Guang-Yan Yu b, Yan Gao a,* a Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing 100081, PR China b Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, PR China article info summary Article history: Oncocytic carcinoma (OC) of salivary gland origin is an extremely rare proliferation of malignant onco- Received 31 May 2010 cytes with adenocarcinomatous architectural phenotypes, including infiltrative qualities. To help clarify Received in revised form 26 July 2010 the clinicopathologic and prognostic features of this tumor group, herein, we report 12 OC cases arising Accepted 27 July 2010 from the salivary glands, together with follow-up data and immunohistochemical observations. There Available online 16 September 2010 were 10 males and 2 females with an age range of 41 to 86 years (median age: 61.3 years). Most occurred in the parotid gland (10/12) with one in the palate and one in the retromolar gland. The tumors were Keywords: unencapsulated and often invaded into the nearby gland, lymphatic tissues and nerves. The neoplastic Oncocytic carcinoma cells had eosinophilic granular cytoplasm and round vesicular nuclei with prominent red nucleoli. Ultra- Salivary gland Clinicopathologic structural study, PTAH, and immunohistochemistry staining confirmed the presence of numerous mito- Immunohistochemistry chondria in the cytoplasm of oncocytes.
    [Show full text]
  • PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
    PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information.
    [Show full text]
  • The Health-Related Quality of Life of Sarcoma Patients and Survivors In
    Cancers 2020, 12 S1 of S7 Supplementary Materials The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of A Nationwide Observational Study (PROSa) Martin Eichler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Susanne Singer, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Vitali Heidt, Christine Hofbauer, Marius Fried, Verena I. Gaidzik, Karl Verpoort, Marit Ahrens, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K. Schuler and the PROSa study group Includes Entities We included sarcomas according to the following WHO classification. - Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. 468 p. (World Health Organization classification of tumours). - Kurman RJ, International Agency for Research on Cancer, World Health Organization, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. 307 p. (World Health Organization classification of tumours). - Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19. - World Health Organization, Swerdlow SH, International Agency for Research on Cancer, editors. WHO classification of tumours of haematopoietic and lymphoid tissues: [... reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25 - 27, 2007]. 4. ed.
    [Show full text]
  • Iodine-. 13 1 Therapy for Parotid Oncocytoma
    Iodine-. 13 1 Therapy for Parotid Oncocytoma Shigeru Kosuda, Masazumi Ishikawa, Kohei Tamura, Miwako Mukai, Atsushi Kubo, and Shozo Hashimoto Department ofRadiology, Okura National Hospital and Keio University Hospital, Tokyo, Japan We presenta rarecaseofa patientwithcoexistingparotidoncocytomaandchronic thyroiditis who received two therapeutic doses of [131ljiodidefor a recurrent oncocytoma (oxyphilic granular cell adenoma), resulting in a definite reduction in tumor volume. We suggest thatradiolodinetherapyfora recurrentoncocytomais an effectiveformof tumor therapy. J Nucl Med 29: 1126—1129,1988 oxic thyroid adenomas represent the only benign SecondAdmission(February2, 1985) lesions ofthe thyroid which have been reported to have From3 mo priorto thesecondadmission,thepatienthad been treated with radioactive iodine therapy (1—4). complained of pain and swelling at the same site due to Parotid oncocytoma, or oxyphilic granular cell ade recurrence. Iodine-l23 (1231)scintigraphy revealed extrathy noma, is an uncommon and benign tumor. It is known roidal accumulation in the recurrent left parotid mass. No activity was seen in the region of the thyroid gland. The that the parotid oncocytomas, as well as Warthin's recurrent tumor did not discharge 1231on washout by lemon. tumors, take up both radioiodine and pertechnetate The patient refuseda second surgicalprocedure. because they originate from salivary duct epithelium (5—9). Iodine-131 Therapy We have encountered an unprecedented case of a Before we tried a new approach of radioiodine
    [Show full text]
  • Genitourinary Pathology (Including Renal Tumors)
    LABORATORY INVESTIGATION THE BASIC AND TRANSLATIONAL PATHOLOGY RESEARCH JOURNAL LI VOLUME 99 | SUPPLEMENT 1 | MARCH 2019 2019 ABSTRACTS GENITOURINARY PATHOLOGY (INCLUDING RENAL TUMORS) (776-992) MARCH 16-21, 2019 PLATF OR M & 2 01 9 ABSTRACTS P OSTER PRESENTATI ONS EDUCATI ON C O M MITTEE Jason L. Hornick , C h air Ja mes R. Cook R h o n d a K. Y a nti s s, Chair, Abstract Revie w Board S ar a h M. Dr y and Assign ment Co m mittee Willi a m C. F a q ui n Laura W. La mps , Chair, C ME Subco m mittee C ar ol F. F ar v er St e v e n D. Billi n g s , Interactive Microscopy Subco m mittee Y uri F e d ori w Shree G. Shar ma , Infor matics Subco m mittee Meera R. Ha meed R aj a R. S e et h al a , Short Course Coordinator Mi c h ell e S. Hir s c h Il a n W ei nr e b , Subco m mittee for Unique Live Course Offerings Laksh mi Priya Kunju D a vi d B. K a mi n s k y ( Ex- Of ici o) A n n a M ari e M ulli g a n Aleodor ( Doru) Andea Ri s h P ai Zubair Baloch Vi nita Parkas h Olca Bast urk A nil P ar w a ni Gregory R. Bean , Pat h ol o gist-i n- Trai ni n g D e e p a P atil D a ni el J.
    [Show full text]
  • Homologous Type of Malignant Mixed Mullerian Tumor of the Uterus Presenting As a Cervical Mass
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector CASE REPORT Homologous Type of Malignant Mixed Mullerian Tumor of the Uterus Presenting as a Cervical Mass Umur Kuyumcuoğlu, Ahmet Kale* Department of Obstetrics and Gynecology, Dicle University Medical School, Diyarbakir, Turkey. Malignant mixed Mullerian tumors are composed of a mixture of sarcoma and carcinoma. The carcinomatous element is usually glandular, whereas the sarcomatous element may resemble normal endometrial stroma (homologous or so- called carcinosarcoma). Here, we present a homologous type of malignant mixed Mullerian tumor of the uterus that pre- sented as a cervical mass. We describe a 55-year-old patient who had a cervical mass arising from the uterus. We performed total abdominal hysterectomy and bilateral salpingo-oophorectomy and surgical staging (including (peritoneal washings, suspicious areas or peritoneal surfaces sampled, infracolic omental sampling, pelvic and paraaortic lymph node sampling, and appendectomy). Carcinosarcomas of the uterine cervix are extremely rare, and when a post- menopausal woman with a cervical mass is admitted to the gynecology clinic, the physician should keep in mind that the mass might be a carcinosarcoma. [J Chin Med Assoc 2009;72(10):533–535] Key Words: carcinosarcoma, cervical mass, malignant mixed Mullerian tumors Introduction and pelvic/paraaortic lymphadenectomy are optimal therapy for carcinosarcoma.1,2 Uterine sarcoma is a malignant tumor that arises from Here, we describe an interesting case of carcino- the smooth muscle or connective tissue of the uterus. sarcoma (homologous type of malignant mixed tumor Uterine sarcomas are rare neoplasms of the female of the uterus) that presented as a cervical mass.
    [Show full text]
  • Nationwide Incidence of Sarcomas and Connective Tissue Tumors of Intermediate Malignancy Over Four Years Using an Expert Pathology Review Network
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20135467; this version posted June 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. Prof. Gonzague de Pinieux MD, PhD *1 , Marie Karanian-Philippe MD *2, Francois Le Loarer MD, PhD*3, Sophie Le Guellec MD4 , Sylvie Chabaud PhD2, Philippe Terrier MD 5, Corinne Bouvier MD,PhD6, Maxime Battistella MD,PhD 7, Agnès Neuville MD, PhD3 , Yves-Marie Robin MD 8, Jean- Francois Emile MD, PhD 9 , Anne Moreau MD 10, Frederique Larousserie MD, PhD 11, Agnes Leroux MD12 , Nathalie Stock MD 13, Marick Lae MD 14, Francoise Collin MD15, Nicolas Weinbreck MD16, Sebastien Aubert MD8, Florence Mishellany MD17, Céline Charon-Barra MD15, Sabrina Croce MD, PhD3, Laurent Doucet MD 18, Isabelle Quintin-Rouet MD18 , Marie-Christine Chateau MD19 , Celine Bazille MD20, Isabelle Valo MD21, Bruno Chetaille MD16, Nicolas Ortonne MD22, Anne Gomez-Brouchet MD, PhD4 , Philippe Rochaix MD4, Anne De Muret MD1, Jean-Pierre Ghnassia MD, PhD23 , Lenaig Mescam-Mancini MD 25, Nicolas Macagno MD6, Isabelle Birtwisle-Peyrottes MD26, Christophe Delfour MD19, Emilie Angot MD13, Isabelle Pommepuy MD2, Dominique Ranchere-Vince MD2, Claire Chemin- Airiau MSc2 , Myriam Jean-Denis MSc2, Yohan Fayet PhD2 , Jean-Baptiste Courrèges MSc3 , Nouria Mesli MSc3 , Juliane Berchoud MSc10 , Maud Toulmonde MD, PhD3, Prof.
    [Show full text]
  • Poster: Publikace 2008
    Publikované Práce lékařů Šiklova Patologicko – anatomického ústavu a bioPtické laboratoře s.r.o. za rok 2008 Časopisy s „impact“ faktorem syringofibroadenoma associated with well-differentiated squamous cell 28. Kuroda N., Katto K., Yamaguchi T., Kawada T., ImamuraY., Hes O., Michal M., 42. Vazmitel M., Spagnolo D.V., Němcová J., Michal M., Kazakov D.V.: 1. Alvarado-Cabrero I., Perez-Montiel D.M., Hes, O.: Multicystic urothelial carcinoma. Am J Dermatopathol, 30, 572-574, 2008. Shuin T., Lee G.H.: Chromophobe renal cell carcinoma: Diagnostic ancillary Hidradenoma papilliferum with a ductal carcinoma in situ component. Case report and review of the literature. Am J Dermatopathol, 30, 392-394, 2008. carcinoma of the bladder with gland-like lumina and with signet-ring cells. 17. Kacerovska D., Michal M., Kreuzberg B., Mukensnabl P., Kazakov DV.: application of imprint cytology and fluorescencein situ hybridization of Acral calcified vascular leiomyoma of the skin: a rare clinicopathological chromosomes 10 and 21 in two cases of typical and eosinophilic variants. 43. Vazmitel M., Michal M., Kazakov D.V.: Merkel cell carcinoma with a A case report. Diagn Pathol, 3, 36, 2008. follicular lymphocytic infiltrate: report of two cases. Am J Dermatopathol, 2. Beneš Z., Chlumská A., Antoš Z., Kohout P., Sequens R.: Detection of variant of cutaneous vascular leiomyomas: report of 3 cases. J Amer Acad Med Mol Morphol, 41, 227-232, 2008. 29. Kuroda N., Kato K., Tamura M., Shiotsu T., Hes O., Michal M., Hagashima 30, 389-391, 2008. carcinoma by means of endoscopic cytoscopy in the area of ulcerative colitis. Dermatology, 59,1000-1004, 2008.
    [Show full text]
  • 2. Cancer NOMENCLATURE HYSTOPATHOLOGY-STUDENTS
    Why it is important to give the right name to a CANCER disease understanding the pathology and/or histology of CANCER cancer helps you: • to make a correct diagnosis (fundamental Nomenclature - Histopathology step for a correct therapy) • to formulate a better research question (fundamental for studying the etiology, the molecular pathogenesis, and the progression of the disease) • to design novel targeted therapeutic strategies Cancer is not a single static state Neoplasia but a progression and mixture of phenotypic and genetic/epigenetic • Benign tumours : changes that proceed toward – Will remain localized – Cannot (by definition= DOES NOT) spread greater aggressive biological to distant sites behavior – Generally can be locally excised – Patient generally survives Mutation in Mutation in Increasing • Malignant tumours: gene A gene B,C, etc. chromosomal aneuploidy – Can invade and destroy adjacent structure – Can (and OFTEN DOES) spread to distant Normal Cell Increased Benign neoplasia Carcinoma proliferation sites – Cause death (if not treated ) Cancer Hystopathology Diagnosis Neoplasia • Biopsy • two basic components: • Fine-Needle aspiration (FNA) – Parechyma: made up of neoplastic cells • Exfoliative cytology (pap smear) – Stroma: made up of non -neoplastic, • Biochemical markers (PSA, CEA, Alpha- host -derived connective tissue and fetoprotein) blood vessels The parenchyma: The stroma: Determines the Carries the blood biological behavior of the supply tumor Provides support for From which the tumour the growth of the derives its name parenchyma 1. Principle of nomenclature NOMENCLATURE (1) Benign tumors Attaching the suffix “-oma” to the type of cell (glandular, muscular, stromal, etc) The most basic classification plus the organ: e.g., adenoma of thyroid. of human cancer is the More detail: organ or body location in The name of organ and derived tissue/ cell + morphologic character + oma which the cancer arises e.
    [Show full text]
  • Acinic Cell Carcinoma of the Salivary Gland: a Continuing Medical Education Case Diane A
    CME/MOC Section Editor: Daniel F. I. Kurtycz, M.D. Jointly sponsored by the University of Wisconsin School Authors: Robert T. Pu, M.D., Ph.D., Assistant Professor, of Medicine and Public Health, Office of Continuing Pro- Co-Director, UM Cancer Center Tissue Core, Department of fessional Development in Medicine and Public Health and Pathology, The University of Michigan Medical School, the Wisconsin State Laboratory of Hygiene. Ann Arbor, Michigan; Diane A. Hall, M.D., Ph.D., Surgical Statement of Need: To reinforce the diagnostic features Pathology Fellow, Department of Pathology, The University of medullary carcinoma and to reacquaint the reader with of Michigan, Ann Arbor, Michingan. the clinical laboratory tests needed to support this diagnosis. Educational Reviewer: Daniel F. I. Kurtycz, M.D., Pro- Target Audience: Cytopathologists, cytopathology fel- fessor, Department of Pathology and Laboratory Medicine, lows, and other healthcare professionals. Wisconsin School of Medicine and Public Health, Medical Learning Objectives: After completing this exercise, Director, Wisconsin State Laboratory of Hygiene. participants should be able to: Disclosure of Faculty Relationships: As a sponsor accredited by the ACCME, it is the policy of the University 1. Identify the general features of medullary carcinoma of Wisconsin School of Medicine and Public Health to of the thyroid. require the disclosure of the existence of any significant fi- 2. Describe the cytologic morphology of medullary nancial interest or any other relationship a faculty member carcinoma of the thyroid derived from Fine Needle or a sponsor has with either the commercial supporter(s) of Aspiration samples. this activity or the manufacturer(s) of any commercial 3.
    [Show full text]
  • The 2015 World Health Organization Classification of Lung Tumors: New Entities Since the 2004 Classification
    PATHOLOGICA 2018;110:39-67 GIPP (GRUPPO ITALIANO DI STUDIO DI PATOLOGIA PLEUROPOLMONARE) • REVIEW The 2015 World Health Organization Classification of lung tumors: new entities since the 2004 Classification M.C. MENGOLI1, F.R. LONGO2, F. FRAGGETTA2, A. CAVAZZA3, A. DUBINI4, G. ALÌ5, F. GUDDO6, E. GILIOLI7, G. BOGINA8, N. NANNINI9, F. BARBISAN10, N. DE ROSA11, G. FALCONIERI12, G. ROSSI13, P. GRAZIANO14 1 Pathology Unit, Azienda Unità Sanitaria Locale/IRCCS Reggio Emilia; 2 Pathology Unit, Azienda Ospedaliera per l’Emergenza Cannizzaro Hospital, Catania, Italy; 3 Pathology Unit, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy; 4 Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy; 5 Pathology Unit, University Hospital of Pisa, Italy; 6 Pathology Unit, Ospedale V. Cervello, Palermo, Italy; 7 Pathology Unit, University and Hospital Trust, Verona, Italy; 8 Pathology Unit, Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy; 9 Department of Cardiothoracic and Vascular Sciences, University of Padova, Italy; 10 Pathology Unit, Ospedali Riuniti of Ancona, Italy; 11 Department of Oncology and Anatomic Pathology, Hospital Vincenzo Monaldi of Napoli, Italy; 12 Department of Pathology, Policlinico di Cattinara, University of Trieste, Italy; 13 Pathology Unit, Azienda USL Valle d’Aosta, Regional Hospital “Parini”, Aosta, Italy; 14 Pathology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy Key words NUT carcinoma • Angiomatoid fibrous histiocytoma • Myxoid sarcoma • PEComatous tumors • Epithelial-myoepithelial carcinoma Summary In the last few years different new pulmonary neoplastic cally and genetically characterized albeit not yet included in lesions have been recognised and some of them, namely NUT the 2015-WHO classification. carcinoma, PEComatous tumors, pneumocytic adenomyoepi- In the present paper we summarised the clinical, morphological, thelioma, pulmonary myxoid sarcoma, myoepithelial tumors/ immunohistochemical and molecular features of these new enti- carcinomas entered in the last 2015-WHO classification of ties.
    [Show full text]